Literature DB >> 26971534

Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.

Kevin Leu1,2,3, Jerrold L Boxerman4, Albert Lai5,6, Phioanh L Nghiemphu5,6, Whitney B Pope2, Timothy F Cloughesy5,6, Benjamin M Ellingson7,8,9,10,11.   

Abstract

PURPOSE: To evaluate a leakage correction algorithm for T1 and T2* artifacts arising from contrast agent extravasation in dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) that accounts for bidirectional contrast agent flux and compare relative cerebral blood volume (CBV) estimates and overall survival (OS) stratification from this model to those made with the unidirectional and uncorrected models in patients with recurrent glioblastoma (GBM).
MATERIALS AND METHODS: We determined median rCBV within contrast-enhancing tumor before and after bevacizumab treatment in patients (75 scans on 1.5T, 19 scans on 3.0T) with recurrent GBM without leakage correction and with application of the unidirectional and bidirectional leakage correction algorithms to determine whether rCBV stratifies OS.
RESULTS: Decreased post-bevacizumab rCBV from baseline using the bidirectional leakage correction algorithm significantly correlated with longer OS (Cox, P = 0.01), whereas rCBV change using the unidirectional model (P = 0.43) or the uncorrected rCBV values (P = 0.28) did not. Estimates of rCBV computed with the two leakage correction algorithms differed on average by 14.9%.
CONCLUSION: Accounting for T1 and T2* leakage contamination in DSC-MRI using a two-compartment, bidirectional rather than unidirectional exchange model might improve post-bevacizumab survival stratification in patients with recurrent GBM. J. Magn. Reson. Imaging 2016;44:1229-1237.
© 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  DSC-MRI; bevacizumab; bidirectional contrast agent flux; glioblastoma; leakage correction; perfusion MRI

Mesh:

Substances:

Year:  2016        PMID: 26971534     DOI: 10.1002/jmri.25227

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  18 in total

1.  pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.

Authors:  Jingwen Yao; Caleb Hock Pang Tan; Jacob Schlossman; Ararat Chakhoyan; Catalina Raymond; Whitney B Pope; Noriko Salamon; Albert Lai; Matthew Ji; Phioanh L Nghiemphu; Linda M Liau; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2019-02-26       Impact factor: 4.130

2.  Effects of MRI Protocol Parameters, Preload Injection Dose, Fractionation Strategies, and Leakage Correction Algorithms on the Fidelity of Dynamic-Susceptibility Contrast MRI Estimates of Relative Cerebral Blood Volume in Gliomas.

Authors:  K Leu; J L Boxerman; B M Ellingson
Journal:  AJNR Am J Neuroradiol       Date:  2016-12-29       Impact factor: 3.825

3.  Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.

Authors:  Kevin Leu; Garrett A Ott; Albert Lai; Phioanh L Nghiemphu; Whitney B Pope; William H Yong; Linda M Liau; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2017-05-25       Impact factor: 4.130

4.  Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of imaging in the management of progressive glioblastoma in adults.

Authors:  Derek Richard Johnson; Chad Allan Glenn; Ramin Javan; Jeffrey James Olson
Journal:  J Neurooncol       Date:  2021-10-25       Impact factor: 4.130

Review 5.  An Update on the Approach to the Imaging of Brain Tumors.

Authors:  Katherine M Mullen; Raymond Y Huang
Journal:  Curr Neurol Neurosci Rep       Date:  2017-07       Impact factor: 5.081

6.  Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma.

Authors:  Benjamin M Ellingson; Jingwen Yao; Catalina Raymond; David A Nathanson; Ararat Chakhoyan; Jeremy Simpson; James S Garner; Alan G Olivero; Lars U Mueller; Jordi Rodon; Elizabeth Gerstner; Timothy F Cloughesy; Patrick Y Wen
Journal:  Clin Cancer Res       Date:  2020-04-08       Impact factor: 12.531

7.  Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.

Authors:  Hiroyuki Tatekawa; Akifumi Hagiwara; Hiroyuki Uetani; Jingwen Yao; Talia C Oughourlian; Shadfar Bahri; Chencai Wang; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2020-09-14       Impact factor: 4.130

8.  Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas.

Authors:  Jerrold L Boxerman; Chad C Quarles; Leland S Hu; Bradley J Erickson; Elizabeth R Gerstner; Marion Smits; Timothy J Kaufmann; Daniel P Barboriak; Raymond H Huang; Wolfgang Wick; Michael Weller; Evanthia Galanis; Jayashree Kalpathy-Cramer; Lalitha Shankar; Paula Jacobs; Caroline Chung; Martin J van den Bent; Susan Chang; W K Al Yung; Timothy F Cloughesy; Patrick Y Wen; Mark R Gilbert; Bruce R Rosen; Benjamin M Ellingson; Kathleen M Schmainda
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

9.  Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study.

Authors:  Hiroyuki Tatekawa; Jingwen Yao; Talia C Oughourlian; Akifumi Hagiwara; Chencai Wang; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Noriko Salamon; Benjamin M Ellingson
Journal:  Clin Nucl Med       Date:  2020-12       Impact factor: 10.782

10.  Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.

Authors:  Kathleen M Schmainda; Melissa A Prah; Helga Marques; Eunhee Kim; Daniel P Barboriak; Jerrold L Boxerman
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 13.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.